Meeting
2018 ASCO Annual Meeting
A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Authors
Andrew Jenho Yee
Massachusetts General Hospital Cancer Center, Boston, MA
Andrew Jenho Yee , Jacob Laubach , Erica Leigh Campagnaro , Brea Lipe , Omar Nadeem , Craig Cole , Elizabeth O'Donnell , Robert L. Schlossman , Giada Bianchi , Andrew Robert Branagan , Samantha J. Shapiro , Cynthia C. Harrington , Jill N. Burke , Marilyn T. Gammon , Kathleen J. Lively , Cassandra Ann Thorburn , Mason L. Mann , Jens Guenter Lohr , Paul G. Richardson , Noopur S. Raje
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT02718833
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8012)
DOI
10.1200/JCO.2018.36.15_suppl.8012
Abstract #
8012
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto
Poster
2019 ASCO Annual Meeting
Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).
First Author: Paul G. Richardson
Poster
2014 ASCO Annual Meeting
A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM).
First Author: David H. Vesole